{
  "docId": "019de071-38a0-778d-8d39-45a206af86ac",
  "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e",
  "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 69,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "other",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The slide uses a timeline-like structure to show dose escalation cohorts for IV and SC administration.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/56",
  "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac",
  "deckJsonHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac.json",
  "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.94,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "SAD and MAD study cohorts",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4840b92f-75b8-406a-9ede-621221277aa9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "list",
      "text": "Broad dose range investigated with both IV and SC formulations (up to 80 mg/kg and 60 mg/kg respectively)\n102 subjects dosed (70 in SAD, 32 in MAD) yielding comprehensive clinical, PK/PD and biomarker dataset\n75 subjects exposed to ARGX-117",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3497973-216e-4d35-b6d2-fd96f9f8a1f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.8,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "IMP = Investigational Medicinal Product\n*IMP administered on Days 1, 8, 15 & 22\n#IMP administered on Days 1, 8 & 22",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c712ef5d-49eb-403c-94d2-2c7545058aa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Ongoing Robust Phase 1 First-in-Human Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffa8f11f-b369-4ba1-9a98-882c81614a20",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 69,
      "from": 46,
      "beatId": "20be018b-29e0-462d-a14d-4277066d2678",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Conclusion and Q&A session",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}